核医学公司Curium Pharma宣布以80亿美元（约540亿人民币）收购Lantheus Holdings，创核药领域历史最大并购纪录[1]。本次交易采用现金加里程碑支付方式，其中基础对价为70亿美元，每股现金对价102.5美元，另设最高12美元/股的或有对价权益（CVR），该权益将根据2030年前的销售里程碑实现情况触发[1]。交易对价较公告前60日加权均价溢价38%，已获得Lantheus董事会全票通过，预计于2027年上半年完成交割[1]。
并购完成后，Curium将获得Lantheus旗下PSMA显像剂Pylarify等产品，实现同位素产能、诊断入口和治疗管线的全链条整合[1]。Curium首席执行官Renaud Dehareng表示："Lantheus是理想的合作伙伴，加速了我们一直在构建的诊疗一体化平台"[1]。合并后的运营将覆盖逾70个国家[1]。Lantheus2026年第一季度的营收为3.773亿美元[1]。
Curium Pharma has unveiled what marks the largest merger in the radiopharmaceutical sector, agreeing to acquire Lantheus Holdings for a transaction valued at up to $8 billion, equivalent to approximately 54 billion yuan [1]. Under the agreement signed on August 3, 2026, Curium will pay $102.50 per share in cash, with additional contingent value rights of up to $12 per share contingent on hitting sales milestones by 2030, translating to a base consideration of $7 billion with the deal capped at $8 billion [1]. The offer represents a 38% premium over Lantheus's weighted average stock price from the preceding 60 days [1]. Lantheus's board of directors unanimously approved the transaction [1].
The acquisition will enable Curium to consolidate its diagnostic-therapeutic platform by obtaining Lantheus's key assets, including the PSMA imaging agent Pylarify, while strengthening its isotope production capacity and treatment pipeline [1]. Following completion, the combined entity will operate across more than 70 countries [1]. Curium CEO Renaud Dehareng stated that "Lantheus is an ideal partner, accelerating the diagnostic-therapeutic integrated platform we have been building" [1]. The transaction is expected to close in the first half of 2027 [1]. Lantheus reported first-quarter 2026 revenue of $377.3 million [1].
